Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

BACKGROUND: High-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) levels. We evaluated the impact of treatment with eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Venu, Kumar, Anirudh, Patel, Divyang R, St John, Julie, Riesmeyer, Jeffrey, Weerakkody, Govinda, Ruotolo, Giacomo, Wolski, Kathy E, McErlean, Ellen, Cremer, Paul C, Nicholls, Stephen J, Lincoff, A Michael, Nissen, Steven E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073792/
https://www.ncbi.nlm.nih.gov/pubmed/32179516
http://dx.doi.org/10.1136/bmjdrc-2019-000943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073792/
https://www.ncbi.nlm.nih.gov/pubmed/32179516
http://dx.doi.org/10.1136/bmjdrc-2019-000943

Ejemplares similares